Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Avista Healthcare and Envigo, an early stage non-clinical contract research organization jointly announced that they have entered into a definitive merger agreement.
read more
Tuesday, December 19, 2017
Avista has completed extensive facility upgrades at its Longmont, Colorado site.
read more
Wednesday, November 02, 2022
Avirmax CMC Inc. has completed its brand-new facility in Hayward, CA (San Francisco Bay Area). The facility has received cGMP license approval by the California Department of Public Health (CDPH)-Food & Drug Branch, for the production of rAAV drug ...
read more
Iovance Biotherapeutics has selected Avid to provide process development, pilot-batch manufacturing and CGMP manufacturing services to support development of IOV-3001.
read more
Avid announced that Acumen has selected Avid to provide process development and clinical manufacturing services in support of ACU193.
read more
Thursday, August 27, 2020
Mapp has contracted Avid to provide process transfer, scale-up and clinical manufacturing services to support one of its development programs for a novel antiviral drug candidate.
read more
Avid Bioservices and Argonaut announced an to provide clients an integrated manufacturing solution including process development, drug substance manufacturing, and drug product manufacturing.
read more
Avid Bioservices announced the completion of two expansions within the company’s mammalian cell facilities. The company expects that the first customer for the newly expanded CGMP mammalian cell suites will begin manufacture this month.
read more
Avid Bioservices Inc., a dedicated biologics contract development and manufacturing organization (CDMO), announced that it will serve as the commercial manufacturer for the humanized monoclonal antibody portion of ZYNLONTA™ (loncastuximab tesirine-...
read more
Avid Bioservices, Inc. announced that the company is further expanding its process development capacity for its mammalian cell business. As part of these efforts, Avid is expanding its state-of-the-art laboratories which could support an additional $...
read more
Tuesday, February 24, 2026
Avid Bioservices announced the grand opening of its new Early Phase Center of Excellence, a state-of-the-art 78,000 square foot facility located in Costa Mesa, California.
read more
Avid Bioservices, Inc. announced the opening of the analytical and process development (AD/PD) suites within the company’s new, world-class viral vector development and CGMP manufacturing facility.
read more
Avid Bioservices has signed two new contract manufacturing service agreements to support the development of novel drug candidates.
read more
Avid Bioservices, Inc. , a biologics contract development and manufacturing organization (CDMO) announced that it has completed construction of CGMP manufacturing suites within its new, world-class cell and gene therapy (CGT) development and CGMP ...
read more
Thursday, February 25, 2021
Avid Bioservices announced the initiation of Phase 2 of the company’s two-phase effort to expand the overall manufacturing capacity within its Myford facility.
read more